Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Retatrutide (LY3437943) is an agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors. Its dose-response relationships with respect to side effects, safety, and efficacy for the treatment of obesity are not known. METHODS: We conducted a phase 2, double-blind, randomized, placebo-controlled trial involving adults who had a body-mass index (BMI, the weight in kilograms divided by the square of the height in meters) of 30 or higher or who had a BMI of 27 to less than 30 plus at least one weight-related condition. Participants were randomly assigned in a 2:1:1:1:1:2:2 ratio to receive subcutaneous retatrutide (1 mg, 4 mg [initial dose, 2 mg], 4 mg [initial dose, 4 mg], 8 mg [initial dose, 2 mg], 8 mg [initial dose, 4 mg], or 12 mg [initial dose, 2 mg]) or placebo once weekly for 48 weeks. The primary end point was the percentage change in body weight from baseline to 24 weeks. Secondary end points included the percentage change in body weight from baseline to 48 weeks and a weight reduction of 5% or more, 10% or more, or 15% or more. Safety was also assessed. RESULTS: We enrolled 338 adults, 51.8% of whom were men. The least-squares mean percentage change in body weight at 24 weeks in the retatrutide groups was -7.2% in the 1-mg group, -12.9% in the combined 4-mg group, -17.3% in the combined 8-mg group, and -17.5% in the 12-mg group, as compared with -1.6% in the placebo group. At 48 weeks, the least-squares mean percentage change in the retatrutide groups was -8.7% in the 1-mg group, -17.1% in the combined 4-mg group, -22.8% in the combined 8-mg group, and -24.2% in the 12-mg group, as compared with -2.1% in the placebo group. At 48 weeks, a weight reduction of 5% or more, 10% or more, and 15% or more had occurred in 92%, 75%, and 60%, respectively, of the participants who received 4 mg of retatrutide; 100%, 91%, and 75% of those who received 8 mg; 100%, 93%, and 83% of those who received 12 mg; and 27%, 9%, and 2% of those who received placebo. The most common adverse events in the retatrutide groups were gastrointestinal; these events were dose-related, were mostly mild to moderate in severity, and were partially mitigated with a lower starting dose (2 mg vs. 4 mg). Dose-dependent increases in heart rate peaked at 24 weeks and declined thereafter. CONCLUSIONS: In adults with obesity, retatrutide treatment for 48 weeks resulted in substantial reductions in body weight. (Funded by Eli Lilly; ClinicalTrials.gov number, NCT04881760.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Retatrutide is the first triple agonist (acting on GLP-1/GIP/glucagon receptors) with published phase 2 data in people with obesity as well as in people with T2D.”
From Triple Agonism Based Therapies for Obesity (2025) · cites this paper as [45]
Experimental — accuracy not yet measuredIn the citing paper
“e24.2 (95% CI, e26.6 to e21.8) in the 12 mg with an ID of 2 mg group as compared with e2.1 (95% CI, e3.5 to e0.7) in the placebo group.”
From Emerging pharmacotherapies for obesity: A systematic review (2025) · cites this paper as Jastreboff et al, 2023
In the citing paper
“Retatrutide 1-12 mg/week over 48 weeks (primary endpoint for bodyweight: 24 weeks) Up to 22•1% (19•3-24•9) with 12 mg/week Up to 0•5% (0•3-0•6) with 8 mg (initial dose 2 mg)/week High drug discontinuation due to adverse events (up to 16% with 12 mg/week); discontinuation for any reason up to 23•5% (with 4 mg/week); weight plateau not reached Jastreboff et al (2023) 138”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [138]
In the citing paper
“In the retatrutide phase 2 trial for people with overweight or obesity (BMI ≥30 kg/m²), or with a BMI of at least 27 kg/m² with one or more weight-related condition, the mean bodyweight reduction at week 48 in the retatrutide (12 mg once-weekly) groups was up to 24•2% (95% CI 21•8-28•6) compared with 2•1% (0•7-3•5) with placebo.138”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [138]
In the citing paper
“However, these resulted in not-so-rare incidents of therapy discontinuation, and their intensity was clearly linked with higher dosages.”
From Retatrutide—A Game Changer in Obesity Pharmacotherapy (2025) · cites this paper as [39]
114 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
The Physical Activity Guidelines for Americans
Piercy, K. L., Troiano, R. P., Ballard, R. M., Carlson, S. A., Fulton, J. E., Galuska, D. A., George, S. M., & Olson, R. D. (2018) · JAMA · doi:10.1001/jama.2018.14854 · Cited by 9,755
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Self-citationA Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Wadden, T. A., Bailey, T. S., Billings, L. K., Davies, M., Frias, J. P., Koroleva, A., Lingvay, I., O’Neil, P. M., Rubino, D. M., Skovgaard, D., et al. (2021) · JAMA · doi:10.1001/jama.2021.1831 · Cited by 1,114
Self-citationA rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents
Finan, B., Yang, B., Ottaway, N., Smiley, D. L., Ma, T., Clemmensen, C., Chabenne, J., Zhang, L., Habegger, K. M., Fischer, K., et al. (2015) · Nature Medicine · doi:10.1038/nm.3761 · Cited by 645
A new glucagon and GLP-1 co-agonist eliminates obesity in rodents
Day, J. W., Ottaway, N., Patterson, J. T., Gelfanov, V., Smiley, D., Gidda, J., Findeisen, H., Bruemmer, D., Drucker, D. J., Chaudhary, N., et al. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.209 · Cited by 641
Aminian, A., Al-Kurd, A., Wilson, R., Bena, J., Fayazzadeh, H., Singh, T., Albaugh, V. L., Shariff, F. U., Rodriguez, N. A., Jin, J., et al. (2021) · JAMA · doi:10.1001/jama.2021.19569 · Cited by 375
Cited by
Items 701–800 of 1,139
Yang, G., Liu, Y., Xie, J., Zeng, S., Xiong, J., Wei, L., Zhang, H., Su, T., Xu, Y.-X., Huang, L., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71327 · Cited by 1
Pearson, M. J., Willency, J. A., Lin, Y., Abadi, A., Hartman, M. L., Coşkun, T., Ruotolo, G., Duffin, K. L., Haupt, A., Newgard, C. B., et al. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag201
Self-citationMerrild, C., Johansen, V. B. I., Clemmensen, C., & Ranea‐Robles, P. (2026) · The Journal of Physiology · doi:10.1113/jp289817 · Cited by 1
Misra, S., Narayan, R. K., & Kaur, M. (2025) · Journal of Basic and Clinical Physiology and Pharmacology · doi:10.1515/jbcpp-2025-0113 · Cited by 3
Animal models for development of anti-obesity drugs in the age of GLP-1 agents
Culver, A. E., Stayrook, K. R., Comerota, M. M., Oblak, A. L., & Burris, T. P. (2025) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2025.2507766 · Cited by 2
“Similarly, humanized gastric inhibitory polypeptide receptor (GIPR) mouse models have emerged as critical tools, particularly in the context of dual (e.g. tirzepatide) and triple (e.g. retatrutide) incretin modulator drug development with prolific anti-obesity efficacy [20,21].”
Braha, A., Timar, B., Sturza, A., & Timar, R. Z. (2026) · Medicina · doi:10.3390/medicina62081509 · Cited by 2
“There is still no firm evidence that retatrutide has a “direct” nephroprotective effect similar to that of SGLT2 inhibitors or GLP-1 RAs, which have proven efficacy in clinical trials with renal endpoints [132].”
Glucagon-like peptide-1 receptor analogues and beyond: emerging obesity pharmacotherapies
Abburi, K., Melson, E., Miras, A. D., & Papamargaritis, D. (2025) · Panminerva Medica · doi:10.23736/s0031-0808.25.05339-x · Cited by 1
Abusnana, S., Sabbour, H. M., Afandi, B. O., Farghaly, M., Farooqi, M. H., Hafidh, K., Hassanein, M. M., Jabbar, A., Shehab, A., Kalimat, R., et al. (2026) · Vascular Health and Risk Management · doi:10.2147/vhrm.s579970 · Cited by 1
Is Metabolic Surgery Having an Identity Crisis?
COHEN, R. V., Lingay, I., le Roux, C. W., & Sumithran, P. (2023) · Obesity Surgery · doi:10.1007/s11695-023-06786-x · Cited by 1
“Moreover, the anti-obesity pharmacology pipeline is a promising agent that may induce > 20% [3].”
BackgroundMediano, O., & Masa, J. F. (2025) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2025.03.009 · Cited by 3
Liver–pancreas communication in disease and drug development
Jia, Y., Zhu, Q., Pan, Q., Lu, G., & Xiao, J. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.01.018 · Cited by 3
“Phase 2 trials showed that retatrutide achieved up to 17.5% mean weight reduction at 24 weeks in adults with obesity and overweight, along with clinically meaningful improvements in glycaemic control and robust bodyweight reductions in T2DM patients 219,220 .”
InfluentialBrunel, F. M., Parlee, S. D., Li, P., Lu, W., Chabenne, J. R., Pérez–Tilve, D., Finan, B., Kharitonenkov, A., & DiMarchi, R. D. (2026) · Biochemistry · doi:10.1021/acs.biochem.5c00820 · Cited by 2
Bueter, M., Peterli, R., & Salminen, P. T. P. (2024) · Obesity Surgery · doi:10.1007/s11695-024-07494-w · Cited by 1
Incretin-Based Therapies, Obesity-Associated Inflammation, and Atherosclerotic Cardiovascular Risk
Kafol, J., Jug, B., & Fras, Z. (2026) · Cells · doi:10.3390/cells15141293 · Cited by 1
“Retatrutide, a triple GIP/GLP-1/glucagon receptor agonist, and survodutide, a GLP-1/glucagon receptor dual agonist, have produced substantial weight loss in phase 2 obesity trials, while CagriSema combines semaglutide with the amylin analog cagrilintide [108–110].”
GIPR:GCGR co-agonism restores normal weight in obese rodents
Pérez–Tilve, D., Zhang, F., Zhang, Y., Lohman, K., Sorrell, J. E., Vick, A., Müller, T. D., Tschoep, M. H., & DiMarchi, R. D. (2026) · Molecular Metabolism · doi:10.1016/j.molmet.2026.102365 · Cited by 1
“The subsequent discovery of retatrutide as a sustained-action, balanced triple agonist validated this concept clinically [11 — 13] in the demonstration of decreased body weight of 24.2% through 48 weekly doses in non-diabetic individuals with obesity [11], and 16.9% after 36 weeks in obese diabetic…”
InfluentialZhu, F., Castillo-Quan, J. I., Ogawa, T., Wu, Z., Ding, L., Sura, M., Watanabe, Y., Lentschat, H., Fernández-Cárdenas, L. P., Dag, U., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2530979123 · Cited by 2
“…therapy has resorted to use of other agents, most importantly GLP - 1 receptor agonists or polyagonists for GLP - 1R and several closely related hormones, including GIP, glucagon, and amylin, even though these are not normally major hormones in the control of eating behavior (16, 47).”
Wicik, Z., Nowak-Szwed, A., Eyileten, C., Sourij, H., von Lewinski, D., Kistkins, S., Borkowska, J., & Postula, M. A. (2025) · npj Systems Biology and Applications · doi:10.1038/s41540-025-00619-6 · Cited by 1
“7%(8mg)and86%(12mg)at48weeks 52 .”
Recent developments in GPCR signalling in appetite regulation
Brittain, H. R., & Gorvin, C. M. (2026) · Bioscience Reports · doi:10.1042/bsr20250120 · Cited by 1
Lower glucagon response and attenuated hepatic glucagon signaling in MASLD
Kim, S. R., Hwang, Y., Lee, M., Choi, A., Lee, B., Kang, E. S., Cha, B., Kim, K. J., & Lee, Y. (2026) · Diabetes & Metabolism · doi:10.1016/j.diabet.2026.101787 · Cited by 1
Brown, W. A., Sumithran, P., Cowley, M. A., Cohen, R., le Roux, C. W., Schauer, P. R., Agarwal, S., Ard, J., Boza, C., Cargiuolo, J. L., et al. (2026) · Obesity Surgery · doi:10.1007/s11695-026-08692-4 · Cited by 1
Self-citationMin, S. H. (2024) · Journal of Korean Diabetes · doi:10.4093/jkd.2024.25.2.82 · Cited by 2
Galiano, Á., & Notario-Pérez, F. (2026) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-026-00836-z · Cited by 1
Shadbolt, C., & Dowsey, M. M. (2025) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2025.02.779 · Cited by 2
Khokhar, M., Yadav, D., & Sharma, P. (2026) · Indian Journal of Clinical Biochemistry · doi:10.1007/s12291-026-01417-5 · Cited by 1
Expression and functional diversity of the glucagon-like peptide-1 receptor across tumor types
Alba, M. M., Lee, W. H., Lee, J. S. H., Lu, Z., Stiles, B. L., & Ligumsky, H. (2025) · Discover Oncology · doi:10.1007/s12672-025-04097-4 · Cited by 4
“Since then, additional GLP-1R agonists have been developed, along with dual GLP-1R/insulinotropic polypeptide (GIP) receptor agonists and triple agonists targeting the glucagon receptor, which are currently in development [3–5].”
Effects of retatrutide on learning and memory in streptozotocin-induced male diabetic rats
Keskin, U., Altın, E., Melkan Kagan, K. A. R. A., Tekin, B., Cakircoban, K. N., Özatik, F. Y., Arı, N. S., Koçak, A., & Güngör, E. (2026) · Behavioural Brain Research · doi:10.1016/j.bbr.2026.116343 · Cited by 3
Bouhmouch, S., Dubern, B., Terraz, C., & Tounian, P. (2026) · Archives de Pédiatrie · doi:10.1016/j.arcped.2026.105545 · Cited by 1
D’Alessio, D. A., & Campbell, J. E. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70894 · Cited by 1
Breaking the mold: revolutionary new obesity drugs set to transform treatment landscape?
Seetharaman, R., & Pandit, S. (2023) · Journal of Basic and Clinical Physiology and Pharmacology · doi:10.1515/jbcpp-2023-0172 · Cited by 1
Type 2 diabetes remission: multidimensional pharmacological strategies and future perspectives
Liu, Y., Gang, X., Liu, X., Jiang, W., Yang, Y., & Wang, G. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1687601 · Cited by 3
Obesity, Visceral Adiposity, and the Future of Hypertension Treatment
Gallagher, B. D. (2025) · American Journal of Hypertension · doi:10.1093/ajh/hpaf175 · Cited by 1
Bloomgarden, Z. T. (2024) · Journal of Diabetes · doi:10.1111/1753-0407.13568 · Cited by 1
Curto, R., Giglione, C., Cannarella, R., Berisha, H., Hattab, R., Condorelli, R. A., Vignera, S. L., Calogero, A. E., & Magni, P. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108278 · Cited by 2
A New Era in the Medical Management of Obesity
Porterfield, F., Fatima, A., Boaventura, B. C. B., Madhar, A., Srivastava, G., & Stanford, F. C. (2026) · Annual Review of Medicine · doi:10.1146/annurev-med-043024-125437 · Cited by 3
MASLD and the cardiovascular-kidney-liver-metabolic syndrome
Angelidi, A. M., Boutari, C., Kokkorakis, M., Stefanakis, K., Mikhailidis, D. P., Jacob, G., & Mantzoros, C. S. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag023 · Cited by 7
Enteric microbiome and obesity: a multidimensional narrative review
Barat, B., Ghosh, K., Kulkarni, B. P., Banerjee, P., & Ghosh, K. (2025) · Microbial Genomics · doi:10.1099/mgen.0.001562 · Cited by 1
GORD and GLP-1 receptor agonists: an emerging concern for gastroenterologists
Massey, B. T. (2023) · Gut · doi:10.1136/gutjnl-2023-331027 · Cited by 1
“1 2 Newer agents additionally possessing glucose-dependent insulinotropic polypeptide (GIP) RA activity 3 or both GIP and glucagon receptor RA activity 4 have produced weight loss up to 20–25% of total body weight, results that rival those from bariatric surgery.”
BackgroundHudanich, M., Smith, S. N., Marino, A., & Riskin, S. I. (2025) · Cureus · doi:10.7759/cureus.93104 · Cited by 7
“The most recent development of a triple GLP-1 receptor agonist known as retatrutide demonstrated even further improvements in insulin sensitivity, weight loss, and glycemic control [12,13].”
InfluentialBarnett, M. J., Ibe, F. O., & Lam, J. (2026) · Cureus · doi:10.7759/cureus.100953 · Cited by 3
“Current ongoing trials are now investigating triple agonism with examples including retatrutide, targeting GLP-1, GIP, and glucagon receptors [4].”
Li, Z., Wang, X., He, Y., Hu, K., Liu, Y., Zhang, W., Ma, Y., & Jiang, H. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1754925 · Cited by 2
Sachdev, S., Roy, S., & Cheloha, R. W. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.07.642093 · Cited by 1
“For example, activation of glucagon family receptors (GLP1R, GIPR, GCGR) shows therapeutic efficacy in treating type-2 diabetes and obesity 45 ; however, these receptors are expressed in multiple tissues.”
AI-Driven Efficient De Novo design of GLP-1RAs with Extended Half-Life and Enhanced EfficacyPreprint
Wei, T., Cui, X., Lin, J., Zheng, Z., Cui, T., Liu, C., Lin, X., Zhu, J., Ran, X., Hong, X., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.26.645438 · Cited by 1
Intersections between HIV and obesity in emerging economies
Levi, J., Fairhead, C., & Hill, A. M. (2023) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000827 · Cited by 1
“42 www.co-hivandaids.com”
Retatrutide - revolutionary recently developed GLP agonist - literature review
Brzozowska, P., Frańczuk, A., Nowińska, B., Makłowicz, A., Palacz, K. A., & Lenartowicz, I. (2024) · Quality in Sport · doi:10.12775/qs.2024.15.52125 · Cited by 1
Will retatrutide help me lose weight or look ‘shredded’?
Ball, L., & Piatkowski, T. M. (2026) · The Conversation · doi:10.64628/aa.ax6u5kfrj · Cited by 2
Nguyen, T., Hong, L., & Iso, T. (2026) · Cardiorenal Medicine · doi:10.1159/000552517 · Cited by 1
AL-shibil, Z. M. R., & Kadhim, Z. J. (2026) · European Journal of Clinical and Experimental Medicine · doi:10.15584/ejcem.2026.1.26 · Cited by 1
Glucagon-like peptide-1–based pharmacological treatment of obesity: a narrative review
Son, J. W. (2026) · Journal of Korean Medical Association · doi:10.5124/jkma.25.0138 · Cited by 1
Metabolic Flux Adaptations During GLP-1 Receptor Agonist Therapy: Redox Implications
Lee, J., You, J. H., Park, H. J., Roh, J.-L., & Paek, S. H. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00709-4 · Cited by 3
“Thera - peutic innovation now includes dual and triple incretin receptor agonists [4 – 7] as well as orally bioavailable small-molecule formulations [8, 9 ], reflecting ongoing efforts to enhance pharmacodynamic durability.”
Joongpan, W., Boonmuen, N., Sinchai, P., Lapmanee, S., Klamsakul, N., & Pathomthongtaweechai, N. (2026) · Pharmacology Research & Perspectives · doi:10.1002/prp2.70232 · Cited by 3
Recombinant Protein Drugs: A 2025 Update
López‐Laguna, H., Parladé, E., Favaro, M. T. D. P., Palacin, C., Voltà‐Durán, E., Ferrer‐Miralles, N., Corchero, J. L., Rodríguez‐Rodríguez, R., Vázquez, E., Unzueta, U., et al. (2026) · BioDrugs · doi:10.1007/s40259-026-00783-z · Cited by 4
“More recently, retatrutide, a triple incretin agonist, has shown strong promise in both obesity and NASH (non-alcoholic steatohepatitis), further expanding the therapeutic potential of this class [173].”
Ectopic, hepatic GLP-1R agonism enhances the weight loss efficacy of GLP-1 analogues
Douros, J. D., Capozzi, M. E., Novikoff, A., Mokrosiński, J., DUBOIS, B. N., Stock, J., Rohlfs, R., Anderson, M., Jedrzejcyk, D. J., Poulsen, S., et al. (2026) · Molecular Metabolism · doi:10.1016/j.molmet.2026.102327 · Cited by 1
“Unlike their mono-and dual-incretin receptor agonist predecessors, which improve CV function [10 — 13], development of GcgR activating compounds has been challenged by the increased HR and arrhythmia induced by chronic GcgR agonism [2,3,14,15].”
Freinkel, K. O. U., Yehoshua, I., Cohen, B., Peleg, R., & Adler, L. (2024) · BMC Family Practice · doi:10.1186/s12875-024-02324-5 · Cited by 1
“As new medications for weight management are being introduced constantly [20, 21], PCPs are handling many patients who seek these treatments but do not always feel sure enough to provide them.”
BackgroundCurrent management of MASLD in type 2 diabetes
Fernández‐Garibay, V. M., Sarabia-Chao, V., & Chávez-Tapia, N. C. (2026) · HORMONES · doi:10.1007/s42000-026-00763-6 · Cited by 1
Incretin Mimetics in Cancer and Cardiovascular Disease
Leong, D. P., Gong, S., Sattar, N. A., Narayan, V., Reizine, N. M., Gerstein, H. C., & Vellky, J. E. (2026) · JACC CardioOncology · doi:10.1016/j.jaccao.2025.12.003 · Cited by 3
Jiang, J., Liang, Y., Wang, R., Jiang, W., Jing, X., & Yang, M. (2026) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.70343 · Cited by 1
“…challenge: the substantial loss of lean body mass. Emerging evidence indicates that up to 40% of the weight lost with these potent agents is attributable to skeletal muscle, raising concerns about the long-term risk of sarcopenia and functional decline, particularly in older adults [5, 6].”
Medical treatments for obesity: what does the future have in store?
Bassatne, A., & Rizo, I. M. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag274 · Cited by 1
Acute Contractile Effects of Glucagon-like-Peptide-1 Receptor Agonists in the Human Heart
Neumann, J., Kirchhefer, U., Hofmann, B., & Gergs, U. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18040447 · Cited by 1
“In humans, retatrutide elevated heart rate and decreased blood pressure [30,51].”
Beyond GLP1: modulating multiple nutrient-stimulated hormone pathways to reduce cardiovascular risk
Kang, Y. M., Harrington, J., Aroda, V. R., & McGuire, D. K. (2026) · Nature Reviews Cardiology · doi:10.1038/s41569-026-01296-6 · Cited by 1
Cardiometabolic and Diabetes Management in Older Adults
Marion, W., & Neeland, I. J. (2026) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2025.12.005 · Cited by 1
Fármacos basados en GLP-1: mecanismos implicados en el tratamiento de la obesidad
Salvador, J. (2025) · Medicina Clínica (English Edition) · doi:10.1016/j.medcli.2025.107035 · Cited by 13
Glucagon receptor modulation: Its role in diabetes care
Seshadri, K., Sosale, A., Kumar, K. M. P., Reddy, S. C., & CHAWLA, P. M. (2023) · Journal of Diabetology · doi:10.4103/jod.jod_106_23 · Cited by 1
GIP in Cardiovascular and Kidney Disease: From Physiology to Pharmacology
Fano, M. D., Haurum, L. L., Andreasen, C. R., Porcellati, F., & Andersen, A. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70888 · Cited by 5
“Retatrutide is being evaluated in the phase 3 TRIUMPH programme [130], including CV and renal outcome trials, following phase 2 findings demonstrating superior weight loss and improvements in cardiometabolic parameters versus tirzepatide [131].”
Pharmacotherapy of Type 2 Diabetes Mellitus
Jha, P. K., Shukla, H., Makwana, A., & Kakkad, A. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.1002309 · Cited by 4
Ding, H., Wang, M., Zhang, J., Wan, C., Huang, Z., Liu, L., & Liu, J. (2025) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00174.2025 · Cited by 5
Medikamente zur Behandlung von Essstörungen und Adipositas
Himmerich, H., & Benkert, O. (2023) · Springer eBooks · doi:10.1007/978-3-662-67685-1_9 · Cited by 1
Zhang, H., Yu, M., Li, L., Chen, C., & He, Q. (2025) · Journal of International Medical Research · doi:10.1177/03000605251315019 · Cited by 2
Ibrahim, E., Burken, M., Lastra, G., & Manrique‐Acevedo, C. (2024) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00765.2024 · Cited by 3
Impact of incretin analogues on lipid and lipoprotein metabolism in obesity and diabetes
Baragetti, A., & Norata, G. D. (2026) · British Journal of Pharmacology · doi:10.1111/bph.70483 · Cited by 1
Obésité sarcopénique : des étapes décisives et des perspectives prometteuses
Boirie, Y., Guillet, C., Pouget, M., Walrand, S., & Pinel, A. (2023) · Nutrition Clinique et Métabolisme · doi:10.1016/s0985-0562(24)00009-8 · Cited by 1
Chan, Z. H., Omar, A. S., Gill, K., Volucke, G., Azhar, M. M., Haleem, S. M., Sia, J. E., Rahman, O. U., Ahmad, M., Shahid, N., et al. (2026) · Cardiology in Review · doi:10.1097/crd.0000000000001209 · Cited by 2
Obesity: A Multi Perspective of Physiology and Neurobiology Energy Regulation
Meiliana, A., Dewi, N. M., & Wijaya, A. (2024) · The Indonesian Biomedical Journal · doi:10.18585/inabj.v16i1.2840 · Cited by 2
“(152) Fumagalin, a naturally occurring substance extracted from Aspergillus fumigatus in 1949, was known to inhibit angiogenesis.”
BackgroundFarkas, G. J., Solinsky, R. J., & Park, A. (2026) · Archives of Physical Medicine and Rehabilitation · doi:10.1016/j.apmr.2026.02.498 · Cited by 1
The perspectives in obesity and type 2 diabetes therapy: the present and future of incretin therapy
Shestakova, M. V., & Bashlykova, R. O. (2025) · Terapevticheskii arkhiv · doi:10.26442/00403660.2025.10.203366 · Cited by 6
Small Bowel Therapies for Metabolic Disease and Obesity
Boškoski, I., Gualtieri, L., & Matteo, M. V. (2024) · Gastrointestinal Endoscopy Clinics of North America · doi:10.1016/j.giec.2024.06.002 · Cited by 1
SURMOUNTing body weight barriers in type 2 diabetes
Novikoff, A., & Müller, T. D. (2023) · Med · doi:10.1016/j.medj.2023.11.007 · Cited by 1
Development of the Weight and Emotions Scale (WES)
Kanu, C., Kimel, M., GOETZ, I. A., Neff, L. M., Boye, K. S., Stefan, M., & Jordan, J. B. (2026) · Obesity Science & Practice · doi:10.1002/osp4.70119 · Cited by 1
A review of survodutide: a new dual acting agonist
Yathindra, M. R., BHATTACHARJEE, A., PUNDIR, N., PATEL, P., Jacob, N. E., Jossy, P. E., & Seetharaman, R. (2026) · Minerva Endocrinology · doi:10.23736/s2724-6507.26.04406-4 · Cited by 2
Commercially Available Injectables in Diabetes – Insulin, Incretins, and More
Kesavadev, J., Kalra, S., John, M., Unnikrishnan, A., Joshi, S., Sankar, P., Kumar, A., Jothydev, K., & Basanth, A. (2023) · International Journal of Diabetes and Technology · doi:10.4103/ijdt.ijdt_29_23 · Cited by 3
GLP ‐1 Receptor Agonists for Treating Alcohol Use Disorder: A Critical Review
Woo, S., Zhu, G., Castro, C., Phuong, A., Roy, A., Davis, C. N., & Kranzler, H. R. (2026) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.70312 · Cited by 3
Xie, J., Yang, Y., Chen, W., (45927), L. W., Weng, S., Lyu, Q., & Cao, G. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00722-7 · Cited by 1
“The synergistic activation of these three receptors produces metabolic effects that surpass those of single-target or dual-target approaches, simultaneously enhancing energy expenditure, promoting lipolysis, and suppressing appetite [9 ].”
InfluentialBudini, B., Luo, S., Tam, M., Stead, I., Lee, A. S., Akrami, A., Vidal‐Puig, A., & Park, A. (2025) · medRxiv · doi:10.1101/2025.06.09.25328726 · Cited by 1
Oral Health Implications of GLP-1 Receptor Agonists and Other Incretin-Based Therapies
Bijoch, J. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15145358 · Cited by 6
“Its glucagon receptor component adds thermogenic and hepatic effects, and its gastrointestinal and emetic burden during dose escalation is expected to equal or exceed that of currently available agents, which would, in turn, heighten the erosive and cariogenic risks discussed below [15].”
EndoCompass project: research roadmap for diabetes, obesity, and metabolism
Mathieu, C., Meireles, M., Pagotto, U., Wabitsch, M., Banerjee, I., Bartolomé, A., Battelino, T., Beck, J., Chiarelli, F., León, D. D. D., et al. (2025) · European Journal of Endocrinology · doi:10.1093/ejendo/lvaf065 · Cited by 5
Pompa-Mera, E. N., Valle-Hernández, M. M., Maldonado, E. R., Marín, J. A. M., Núñez-Armendáriz, M., & Gaytán‐Martínez, J. (2025) · Nutrición Hospitalaria · doi:10.20960/nh.05562 · Cited by 1
Himanshu, Verma, S., Yadav, S., Singh, A., Chauhan, J., Sameeksha, Sahu, K., & Mamgain, A. K. (2026) · Discover Endocrinology and Metabolism · doi:10.1007/s44417-026-00025-4
“…the development of novel incretin-based therapies, including dual and triple receptor agonists such as tirzepatide and retatrutide, represents a significant advancement in the management of T2DM and obesity, offering unprecedented improvements in glycemic control and weight reduction [115, 116].”
Chen, J. J., Chiru, E.-D., & Shen, S. (2026) · Current Breast Cancer Reports · doi:10.1007/s12609-026-00662-0
Narla, S., & Narla, R. R. (2026) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2026.07.030 · Cited by 1
PHARMACOLOGICAL TREATMENT FOR OBESITY: MECHANISMS OF ACTION, SAFETY AND THERAPEUTIC EFFICACY
dos Santos, R. R. L., Guasti, E. D. P., Nunes, F. M., Leopoldo, A. S., & Lima‐Leopoldo, A. P. (2026) · International Journal of Health Management Review · doi:10.47172/ijhmreview.v12i1.461
“This means that it simultaneously activates three key biological pathways involved in the regulation of appetite, glucose metabolism, and adipose tissue homeostasis (Jastreboff et al., 2023; Urva et al., 2022b).”
Neue Therapien bei Adipositas im Kindesalter
Gomahr, J., & Weghuber, D. (2025) · Journal für Endokrinologie Diabetologie und Stoffwechsel · doi:10.1007/s41969-025-00271-9
O’Brien, H., Byrne, A. J., Franciosi, A. N., & Butler, M. W. (2026) · Pulmonary Therapy · doi:10.1007/s41030-026-00380-z
“Furthermore, the therapeutic landscape of GLP-1 therapies is continuing to evolve with several dual and triple hormone receptor agonists currently undergoing phase 2 and 3 clinical trials [86, 87].”
soler, J. J. G. (2025) · Galicia Clínica · doi:10.22546/86/1/1447
Hailu, K. T., Abriha, F. N., Duguma, Y. M., Haddad, R. R., Liyew, T., & Kasagga, A. (2026) · Cureus · doi:10.7759/cureus.110657 · Cited by 2
Senatorska, N., Kleszczewska, K., Pruska, A., Rarok, J., Godlewska, D., Pietruszewska, H., Banaszek, M., Panfil, A., Błocka, J., & Lurka, A. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.4(48).2025.4225
Ciancimino, G., Pecorella, F., Viscardi, S. M., Mantia, C. L., Caserta, A., Pennisi, G., & Petta, S. (2026) · Hepatoma Research · doi:10.20517/2394-5079.2026.19
Neue Medikamente zur Gewichtsreduktion – ethische Herausforderungen
Weidinger, I. S. (2026) · Aktuelle Ernährungsmedizin · doi:10.1055/a-2840-0244
Shokravi, A., Singh, R., Sharma, S., Seth, J., & Mancini, G. B. J. (2026) · CJC Open · doi:10.1016/j.cjco.2026.02.008 · Cited by 1
Díaz, L. A. H., Alanis, B. A. L., Zorrilla-Núñez, L. F., & Muñoz-Maldonado, G. E. (2026) · Cureus · doi:10.7759/cureus.113460
Włodarczyk, A., Łagosz, H., Wites, P., Wites, K., Piotrowski, P., Jabłońska, A., Pyzik, M., Ziółkowska, K., Markusiewicz, K., & Bahyrycz, P. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(51).2026.6101
Metadata
- Authors
- Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., & Hartman, M. L.
- Affiliations
- Harvard University (US)
- From the Departments of Medicine (Endocrinology and Metabolism) and Pediatrics (Pediatric Endocrinology), Yale University School of Medicine, New Haven, CT (A.M.J.); the Obesity and Metabolism Institute and Department of Medicine, Harvard Medical School, Boston (L.M.K.); Velocity Clinical Research, Los Angeles (J.P.F.); and Eli Lilly, Indianapolis (Q.W., Y.D., S.G., T.C., A.H., Z.M., M.L.H.).
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-08-10
- Volume
- 389
- Issue
- 6
- Pages
- 514-526
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4382049661
- Cited by
- 1,174
- References
- 28
- Citations by year
- 2026: 399 · 2025: 366 · 2024: 310 · 2023: 96
- FWCI
- 181.67
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- retatrutide, obesity, weight loss, dose-response relationship, adverse events, GLP-1 receptor agonists, GIP receptor agonist, glucagon receptor agonist, weight-related comorbidities, body mass index
- MeSH terms
- Adult, Double-Blind Method, Female, Gastric Inhibitory Polypeptide, Humans, Injections, Subcutaneous, Male, Obesity, Weight Loss, Body Mass Index, Treatment Outcome, Receptors, Glucagon, Anti-Obesity Agents, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.